ESC 365 - Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

ESC Premium Access

Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

Session: First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Topic: Pharmacotherapy

Speaker: Professor G. Filippatos (Athens, GR)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)

77 presentations

11 followers

7 more presentations in this session

Opening question.

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO

Speaker: Professor M. Packer (Dallas, US)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON

Speaker: Professor A. Voors (Groningen, NL)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

Speaker: Professor M. Packer (Dallas, US)

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON

Speaker: Professor A. Voors (Groningen, NL)

Access the full session

First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Speakers: Professor G. Filippatos, Professor M. Packer, Professor A. Voors, Professor M. Packer, Professor A. Voors

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources